VirtualScopics Inc

VirtualScopics — Shareholder Meeting (June 2014)

40 slides from VirtualScopics's shareholder meeting presentation, Jun 19, 2014

  1. Slide 1: 2014 Annual Shareholders' Meeting

    500 Linden Oaks, 2 nd Floor Rochester, New York 14625 (585) 249 - 6231 www.virtualscopics.com NASDAQ: VSCP 2014 Annual Shareholders’ Meeting June 17, 2014 1

  2. Slide 2: Introductions and Opening Remarks

    Introductions and Opening Remarks • Eric Converse, Interim President & Chief Executive Officer Proxy Summons Financial Review • Jim Groff, Acting Chief Financial Officer Business Development • Erik Jensen, Vice President of Global Business Development & Marketing Technology • Jonathan Riek, PhD., Ch

  3. Slide 3: Eric T. Converse, Interim President & CEO

    Eric T. Converse Interim President & Chief Executive Officer June 17 , 2014 500 Linden Oaks, 2 nd Floor Rochester, New York 14625 (585) 249 - 6231 www.virtualscopics.com NASDAQ: VSCP 3

  4. Slide 4: Forward-looking statements

    This presentation contains forward - looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbors created thereby. These forward - looking statemen

  5. Slide 5: Initial Focus: Employees and Customers

    • Initial Focus - Employees • Training • Positive Changes in the Management Team - Customers • New Names on the RFP Win List • Maintaining and Developing Existing Customers • Ultimate Focus - Delivering Shareholder Value 5

  6. Slide 6: Pipeline and Bookings; IXICO Relationship

    • Pipeline and Bookings Continue to Grow • IXICO Relationship - Close to Signing the Framework Agreement - Scientific Advisory Board Members Identified - Joint Office Target Announcement for Mid - July • Conferences • Investor Relations - Outreach to Existing Investors - Attracting New Investors 6

  7. Slide 7: Financial Update

    Jim Groff Acting Chief Financial Officer June 17 , 2014 500 Linden Oaks, 2 nd Floor Rochester, New York 14625 (585) 249 - 6231 www.virtualscopics.com NASDAQ: VSCP Financial Update 7

  8. Slide 8: Q1 2014 Results and Bookings

    (millions of dollars) As of March 31, 2014 2013 Increase Awards Outstanding & Bookings $ 13.6 $ 4.0 3.4x (thousands of dollars) Three Months Ended March 31, 2014 2013. Change Revenues $92053) MS 52535 (7%) Cost of Services $ 1,595 $ 1,747 (9%) Gross Profit $ 758 $ 786 (4%) Operating Expenses Researc

  9. Slide 9: Balance sheet

    Current assets Cash $ 6.837.572 Accounts receivable, net 1,642,792 Prepaid expenses and other current assets 432.467 Total current assets 5,912,831 Patents, net 1,306,034 Property and equipment, net 198.171 Total assets S_10.417,036 Liabilities and Stockholders’ Equity Current liabilities Accounts p

  10. Slide 10: 2014 outlook

    x We believe 2014 revenues will be relatively flat with 2013 Timing of the initiation of 2013 and 2014 projects The number of projects that closed during 2013 and the first three months of 2014 x We expect operating expenses to trend higher for the remainder of the year Investments in personnel, ope

  11. Slide 11: Awards Outstanding and Bookings

    Q1 2014 Q12013 Change RFPs 40 36 1% (millions of dollars) As of Mar 31, 2014 2013 Increase Awards Outstanding $ 96 $ 12 8.0x Bookings $ 40 $ 28 14x Bookings and Awards Outstanding $ 13.6 $ 40 34x (millions of dollars) As of Mar 31, AsofDec31, % of 2014 2013 2013 Bookings and Awards Outstanding $ 136

  12. Slide 12: Beneficial Ownership Percentages

    15.1% 10.2% 7.1% 5.1% 62.5% Loeb Investors Company Merck Global Health Innovation Fund, LLC University of Rochester Board Members and Executives Stockholders with less than 5% of holdings Beneficial Ownership Percentages As of April 30, 2014 12

  13. Slide 13: Share data and market cap

    • 2.99MM Common shares outstanding • 481M Convertible preferred securities • 474M Warrants/Options • $2.93 - $6.70 NASDAQ 52 week range • ∼ $11.5MM Market cap 13

  14. Slide 14: Business Development Update

    Erik Jensen Vice President Global Business Development and Marketing June 17 , 2014 500 Linden Oaks, 2 nd Floor Rochester, New York 14625 (585) 249 - 6231 www.virtualscopics.com NASDAQ: VSCP Business Development Update 14

  15. Slide 15: Segmented sales and marketing approach

    • Focuses on a segmented and targeted approach relative to account type, sales channel, therapeutic area and study phase • Provides uniform goals and objectives across territories and Business Development Directors • Provides clear promotion and positioning strategies for our core imaging services •

  16. Slide 16: Routes to Market: Direct and Indirect Channels

    16 Routes to Market (Services) – Direct and Indirect Channels VirtualScopics Imaging Solutions Pharmaceutical Companies Direct (VS Sales and Project Management) Channels PPD IXICO

  17. Slide 17: 2014 Spring Educational Webinar Schedule

    7 ¥ VIRTUALSCOPICS 2014 Spring Educational Webinar Schedule i} ra F Virruatscorics TE v V VIRTUALSCOPICS

  18. Slide 18: This image cannot currently be displayed.

    18 This image cannot currently be displayed.

  19. Slide 19: Lead Generation and Proposal Development

    • Lead Generation – Direct and Channel Sales Force (maximizing interaction with existing and new clients) – Conferences, Webinars, eNewsletters, Press Releases, Scientific Posters, Publications, Case studies, White Papers, VirtualScopics website, etc. • Proposal Development – Centralized, integrated

  20. Slide 20: Awards by Therapeutic Area

    20 Jan-May 2013 % of New % ie - Study Awards stu Therapeutic Area (TA) Gustanting Therapeutic Area (TA) ne and Bookings | Outstanding Musculoskeletal 40% Oncology 84.5% Oncology 29% Metabolic 11.1% RA ~ aad Musculoskeletal 3.4% Metabolic 6% eRe ee Device 5% - Central Nervous System 3% Inflammation-o

  21. Slide 21: Recent study awards

    First - ever Program Award for VirtualScopics • Multi - million dollar oncology program award with a top 10 pharmaceutical company New Study Award • New Study Award from a top 10 pharmaceutical c ompany • Global Phase II Myelofibrosis Study New Study Award • New Study Award from a top 15 pharmaceuti

  22. Slide 22: Why was VirtualScopics chosen?

    Why was VirtualScopics chosen? • Our demonstrated scientific capabilit ies in the specific disease indication • Our demonstrated scientific and operational flexibility and responsiveness 22

  23. Slide 23: Technology Update

    Jonathan Riek, Ph.D. Chief Technical Officer June 17 , 2014 500 Linden Oaks, 2 nd Floor Rochester, New York 14625 (585) 249 - 6231 www.virtualscopics.com NASDAQ: VSCP Technology Update 23

  24. Slide 24: Imaging Sites, Image Analysis, Results Delivery

    24 Imaging Sites Image Analysis Results Delivery

  25. Slide 25: Imaging Sites, Image Analysis, Results Delivery

    25 Imaging Sites Image Analysis Results Delivery

  26. Slide 26: Imaging Sites, Image Analysis, Results Delivery

    26 Imaging Sites Image Analysis Results Delivery

  27. Slide 27: Imaging Sites, Image Analysis, Results Delivery

    27 Imaging Sites Image Analysis Results Delivery

  28. Slide 28: A Case Study: Muscle Atrophy

    A Case Study: Muscle Atrophy 28

  29. Slide 29: Becker Muscular Dystrophy study

    • 10 years ago – Wyeth MYO - 029 • Becker Muscular Dystrophy study • Unique ability to perform volumetric analysis 29

  30. Slide 30: Causes of muscle atrophy

    • Many causes of muscle atrophy or muscle wasting: – Sarcopenia (up to 45% of older US population) – Cachexia (about 1% in US, Europe and Japan 9M) – Muscular Dystrophy (500/yr in US) – Disuse (fractures – 1.3% US adult population /yr) – Burns (US – 40,000/yr) – Many others 30

  31. Slide 31: a ¥ VIRTUALSCOPICS

    a a ¥ VIRTUALSCOPICS

  32. Slide 32: Measuring Muscle Mass

    iMeasuring| Muscle] Mass: a 2 ¥ VIRTUALSCOPICS

  33. Slide 33: Innovation Continues

    Edward Ashton, Ph.D. Chief Scientific Officer June 17 , 2014 500 Linden Oaks, 2 nd Floor Rochester, New York 14625 (585) 249 - 6231 www.virtualscopics.com NASDAQ: VSCP Innovation Continues 33

  34. Slide 34: Change in Ktrans vs. AUC correlation

    y = -0.0001x + 0.1096 R 2 = 0.5239 -50.00% -40.00% -30.00% -20.00% -10.00% 0.00% 10.00% 20.00% 30.00% 40.00% 0 500 1000 1500 2000 2500 3000 3500 4000 4500 %Change in Ktrans vs. AUC(0 - 24hr) for MN - 029. Correlation is significant (p<.001) 34

  35. Slide 35: Tumor burden vs. Ktrans reduction

    Tumor Burden Reduction >10% Stable Tumor Burden Tumor Burden Increase >10% K Reduction >60% 16/24 (67%) 4/24 (17%) 4/24 (17%) K Reduction 40% - 60% 32/44 (73%) 4/44 (9%) 8/44 (18%) K Reduction 20% - 40% 17/37 (46%) 7/37 (19%) 13/37 (35%) No Measurable K Reduction 18/67 (27%) 29/67 (43%) 20/67 (30%)

  36. Slide 36: Selected study examples

    36 • VS 94005, metastatic breast cancer: 10,000+ reads completed in five weeks, with flawless delivery. • VS 31403, advanced thyroid cancer: 500+ patients, complex protocol, VS received personal thanks from the study head for our contributions to the program. • VS 34005, tuberous sclerosis: Pivotal

  37. Slide 37: Consistent industry leader

    • VirtualScopics has been a consistent industry leader: – Multi - site DCE - MRI – Tumor volume analysis – Real - time reading – Site - central confirmation reads • Innovation continues… 37

  38. Slide 38: Scientific advisory board

    • Led by VirtualScopics CSO and CTO • Brings together world - class experts across a broad range of indications: – Metabolic diseases – Hepatic MRI – Oncology – Neurology – Cardiology • Ensures that VirtualScopics stays on the cutting edge of imaging in clinical trials. 38

  39. Slide 39: Thank You, Question and Answer

    39 Thank You Question and Answer

  40. Slide 40: Thank You

    40 On behalf of the VirtualScopics ’ Board of Directors and Employees Thank You

VirtualScopics — Shareholder Meeting (June 2014) on 6ix